ClinicalTrialsFinder
RecruitingPhase 2NCT04205604

18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

18F-Fluoro-L- DOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

Sponsor

Miguel Pampaloni

Enrollment

50 participants

Start Date

Nov 3, 2016

Study Type

INTERVENTIONAL

Conditions

Congenital Hyperinsulinism

Summary

The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas to guide surgical resection.

Eligibility

Min Age: 0 DaysMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 18F-Fluoro Dopa Imaging for people with congenital hyperinsulinism. The study is currently recruiting participants at 1 location. People eligible for this study include aged 0 Days to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG18F-Fluoro Dopa Imaging

Imaging with 18F-Fluoro Dopa PET Imaging

Locations(1)

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04205604

Related Trials

18F-DOPA II - PET Imaging Optimization

NCT047069101 location

HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)

NCT047324167 locations

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

NCT020216041 location